Surrozen, Inc. (SRZN)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
Surrozen NASDAQ: SRZN Chief Executive Officer Craig Parker outlined the company's rationale for developing Wnt-targeting retinal disease therapies during H.C. Wainwright's 6th Annual Ophthalmology Investor Conference, emphasizing the company's focus on Frizzled-4 signaling, anti-VEGF activity and, in one preclinical program, IL-6 inhibition.
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround
Surrozen (SRZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Surrozen, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Li Peng China Universal Asset Management Co. Ltd. | 2,500 | $53,320 | $49,325 | -$3,995 | -7.49% |
| KJ Ken Joseph Braidwel LLP | 396,100 | $8.05M | $8.45M | $397,898.5 | 4.94% |
 Kevin Roan Stempoint Capita LLP | 195,981 | $1.86M | $4.41M | $2.55M | 137.19% |
 Ilko Menkov Vestal Point Capita LLP | 338,611 | $9.86M | $7.71M | -$2.15M | -21.82% |
 Yuen Man Lee Persistent Asset Partners Ltd. | 7,143 | $179,611.08 | $154,038.79 | -$25,572.29 | -14.24% |
Surrozen, Inc. (SRZN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Surrozen, Inc. ever had a stock split?
Surrozen, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Craig Parker CEO | NASDAQ (CM) Exchange | 86889P208 CUSIP |
| US Country | 44 Employees | - Last Dividend | 14 Dec 2023 Last Split | 11 Jan 2021 IPO Date |
Overview
Surrozen, Inc. is a pioneering force in the field of biotechnology, focusing on the clinical stage development of innovative drug candidates. With a mission firmly centered around tissue repair and regeneration, Surrozen is at the frontier of manipulating the Wnt signaling pathway—a crucial axis in cellular growth and differentiation. This biotech entity is passionately engaged in crafting antibody-based therapeutics designed to have a transformative impact across a multitude of disease spheres. Since its inception in 2015, Surrozen has made its home in South San Francisco, California, positioning itself in the heart of a vibrant life sciences hub. The company's strategic partnership with Boehringer Ingelheim International GmbH underscores its commitment to advancing the frontiers of medicine through collaborative innovation and the pursuit of groundbreaking R&D initiatives.
Products and Services
- SZN-043: This hepatocyte-specific R-spondin mimetic bispecific fusion protein represents a cornerstone of Surrozen’s pipeline. Currently navigating through a Phase 1b clinical trial, SZN-043 targets severe liver diseases, such as alcoholic hepatitis, showcasing the company’s dedication to addressing critical needs in hepatology. By engaging with the asialoglycoprotein receptor 1, this therapeutic endeavor embodies Surrozen’s innovative approach to liver health and disease management.
- SZN-1326: As a testament to Surrozen’s dedication to combating gastrointestinal disorders, SZN-1326 emerges as a bi-specific antibody currently under the scrutiny of a Phase 1b clinical trial. This promising candidate is engineered to tackle moderate to severe inflammatory bowel disease by targeting the Frizzled and LRP receptors, pivotal components in the modulation of the Wnt signaling pathway and thus inflammation and tissue repair processes.
- SZN-413: Venturing into the realm of ophthalmology, SZN-413 is a Fzd4 targeted bi-specific antibody, presently in the preclinical developmental stage. This innovative therapeutic seeks to mitigate the impact of retinal vascular associated diseases, illuminating Surrozen’s commitment to addressing a wide spectrum of unmet medical needs through the intricate manipulation of the Wnt signaling axis.
